IAM Magazine issue 13August/September 2005
For companies seeking to leverage their IP assets in the financial markets there have never been more products on offer. The trick is to find which one is most suitable
Viewed in isolation, the failure of the CII Directive was not a body blow to European patent owners. The problem is that it was just the latest in a string of reverses that threaten to leave Europe’s businesses way behind their global competition
Setting realistic expectations for IP commercialisation involves a strategic analysis and not just a simple comparison to IBM’s programme
Even companies with great technology and a commitment to license cannot assume that people will beat a path to their doors to take what is on offer. In such cases, the most likely outcome is that there will be very little interest unless a strategy to engage with potential licensors is developed and then implemented
The Chinese government is establishing high-tech standards that differ from those accepted internationally. In effect, therefore, foreign high-tech IP rights are in danger of losing value. But it is not too late for high-tech companies to do something about it
McDonald’s has picked the wrong person to have a trademark fight with in Australia.
At events in Gothenburg and Munich, cutting edge discussions about the future of IP were the order of the day.
If John Roberts successfully navigates the Congressional nomination process and ends up as the Supreme Court’s newest member, his business law credentials could mean good news for US IP owners
A company’s intellectual property assets clearly have value. The problem is finding a way to assess this accurately
There are a number of reasons, many of which have little to do with hardnosed business principles, why letting go of a patent can be difficult. But if companies are to do justice to themselves and their shareholders, they must take the sentimentality out of portfolio management
The Merck v Integra decision handed down by the Supreme Court in early June is good news for pharmaceutical companies
There are many reasons to value a single patent or a whole portfolio. Some are far more relevant to the venture capital community than others
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email